Sun, Dec 28, 2014, 11:09 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

  • solantey@sbcglobal.net solantey Feb 25, 2013 9:34 AM Flag

    "Stocktipster's 2013 Stock of the Year"

    Amarantus Bioscience - AMBS

    Once the public finds out about the huge potential that the company's patented MANF technology offers you'll regret not having bought shares at the current "bargain basement price of seven cents.

    The "Human Brain Mapping Project" is going to start generating any number of articles related to what companies will benefit from the project. I have to believe that Amarantus will be at the forefront of those discussions especially as it relates to small-cap bio-tech companies .

    I think the recent high of .195 will be surpassed within four weeks or sooner.

    A joint venture or partnership takes this to over .50 in a day.

    Be happy that you found out about the company's tremendous upside before 99.9% of the future shareholders.

    Note: Amgen (AMGN) was once a seven cent stock . It's currently trading at $86.82.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • solantey@sbcglobal.net solantey Mar 27, 2013 11:35 AM Flag

      Read today's Yahoo news regarding the company's MANF technology.

    • Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), has appointed Mark Benedyk, Ph.D., to its Board of Directors. Dr. Benedyk has over 18 years of experience as a senior business development executive and consultant to life science companies, and has served as a Corporate Advisor to Amarantus since 2011. With the addition of Dr. Benedyk, the Amarantus board has four members, two of whom are considered independent directors, including Dr. Benedyk.

      “I am excited to join the Amarantus board at such an important stage of the Company’s scientific and business development growth,” said Dr. Benedyk. “I look forward to helping the Company as it advances MANF towards the clinic for Parkinson’s disease, and executes a commercial strategy for its promising clinical diagnostic tests for Parkinson’s and Alzheimer’s disease.”

      Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience, stated “Mark Benedyk has played a significant role in the growth and success of several leading healthcare companies. With his knowledge and understanding of clinical development and regulatory affairs, as well as the financial and operating requirements of a development-stage company, Mark will be an important resource for all aspects of managing our progress and creating value for shareholders.”

      Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy. In this role he serves on the Strategic Advisory Board of KemPharm, Inc., is a Director at the Center for Drug Research and Development Ventures, Inc., and is a member of the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membershi

      • 1 Reply to scanit2008
      • Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), has appointed Mark Benedyk, Ph.D., to its Board of Directors. Dr. Benedyk has over 18 years of experience as a senior business development executive and consultant to life science companies, and has served as a Corporate Advisor to Amarantus since 2011. With the addition of Dr. Benedyk, the Amarantus board has four members, two of whom are considered independent directors, including Dr. Benedyk.
        “I am excited to join the Amarantus board at such an important stage of the Company’s scientific and business development growth,” said Dr. Benedyk. “I look forward to helping the Company as it advances MANF towards the clinic for Parkinson’s disease, and executes a commercial strategy for its promising clinical diagnostic tests for Parkinson’s and Alzheimer’s disease.”
        Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy. In this role he serves on the Strategic Advisory Board of KemPharm, Inc., is a Director at the Center for Drug Research and Development Ventures, Inc., and is a member of the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the TPI Board of Directors, board positions with TPI portfolio companies, oversight of the TPI operations team, and reviewing investment opportunities in multiple technologies.
        Dr. Benedyk has held executive business development roles at Ascenta Therapeutics, Optimer Pharmaceuticals, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals, where he led partnering efforts for several key clinical-stage products for the treatment of Alzheimer’s Disease, migraine and other neurological indications. He received his Ph.D. in Developmental and Molecular Genetics from The Rockefeller University, and Bachelor of Science degree in Microbiology and Botany from the University of Michigan.

    • Get in today under a dime.

      Due diligence.

    • solantey@sbcglobal.net solantey Mar 4, 2013 9:05 AM Flag

      Get in today.

    • solantey@sbcglobal.net solantey Mar 1, 2013 8:09 AM Flag

      Due diligence before it gaps higher.

    • Substantially undervalued. Down 70% from its recent high of .20.

      Due diligence.

 
FB
80.78+0.01(+0.01%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PG&E Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST